MEA Dermatology Diagnostic Devices Market

MEA Dermatology Diagnostic Devices Market Size (2024 to 2029)

As per the research report, the size of the Middle East and Africa Dermatology Diagnostic Devices market was valued at around USD 1.34 billion in 2024 during the forecast period 2024 to 2029. It is expected to grow at a CAGR of 5.2% to reach USD 1.73 billion by 2029. It captures 5% of the global market.

Dermatology devices are expected to grow at a faster rate due to rising concern amongst people regarding aesthetics. This has led to rising awareness about various types of aesthetic procedures used for treating hair- and skin-related disorders. Primarily, women suffer from these disorders. Therefore, they are the highest revenue makers in the market.

Increasing the incidence of skin disorders, growing awareness regarding aesthetic procedures, technological advancements, and rising healthcare expenditure are the primary drivers of the market.

This research report on the MEA Dermatology Diagnostic Devices Market has been segmented and sub-segmented into the following categories:

By Type:

• Dermatoscopes
• Microscopes
• Imaging Devices

By Application:

• Skin Cancer Diagnosis
• Other Diagnostic Applications

By Dermatoscopes:

• Contact Oil Immersion Dermatoscopes
• Cross-Polarized Dermatoscopes
• Hybrid Dermatoscopes      

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The imaging devices category is anticipated to command the largest share of the market during the aforementioned forecast period. This is due to technological advancements and rising awareness regarding aesthetic procedures. The skin cancer diagnosis segment is expected to account for the largest share of the market during the forecast period.

The leading companies leading in the MEA Dermatology Diagnostic Devices Market profiled in the report are 3Gen Inc. (U.S.), Bruker Corporation (U.S.), Carl Zeiss (Germany), Genesis Biosystems, Inc. (U.S.), Alma Lasers, Ltd. (Israel), Cutera, Inc. (U.S.), Cynosure, Inc. (U.S.), Lumenis Ltd. (Israel), Valeant Pharmaceuticals (Canada), HEINE Optotechnik GmbH & Co. KG (Germany), Michelson Diagnostics (U.K.), and PhotoMedex, Inc. (U.S.).